Download Evolution of Immunology in Cancer to Immune-Oncology

Drugs in Immunology
Evolution of
Immunology in Cancer
to Immune-Oncology
Leveraging Self Immunity to
Prevent & Treat Cancer
1908 Advertisement Touting Cancer
Cure
Immunology Drugs in Cancer
1980s
Interferon
❖
❖
❖
Group of signaling proteins made and
released by host cells in response to the
presence of pathogens, such as viruses,
bacteria, parasites, or tumor cells.
First described in 1957 by Alick Isaacs
and Jean Lindenmann at the National
Institute for Medical Research in London
Human beta interferon messenger RNA
was prepared by Tan's lab for Cetus corp.
to clone the human beta interferon gene
in bacteria
My Involvement
In Immunology
1985
My Involvement
In Immunology
1985
1984: The Nobel Prize in Physiology Or
Medicine
Niels K. Jerne
Georges J.F. Köhler
César Milstein
Hybridoma Technology
Immortalizing
Antibody Producing
Cells
❖
❖
1974 Georges J.F. Köhler and César
Milstein describe the hybridoma
technique for production of
monoclonal antibodies
Immortalized antibody producing
cell is fused with tumor cells to
produce unlimited amounts of
monoclonal antibodies with
predetermined specificity
1990s: First Cancer Biologics
The first therapeutic monoclonal antibodies, rituximab (Rituxan)
and trastuzumab (Herceptin) approved for lymphoma and breast
cancer, respectively
Immunology Drugs in Cancer
Cancer Vaccines
❖
❖
❖
❖
Long & drawn out history
Mixed results
Two approved vaccines: Provenge,
Oncophage
2010-2020: A period of Renaissance in
Cancer Vaccines?
Immunology in Cancer Treatment
Ipilimumab
The “Immune-Oncology" Drug
Immuno-Oncology
Blockade of
Immune
Checkpoints
Key Questions…
❖
How will the space of I/O evolve
❖
What will be the role of non-checkpoint blockade
mechanisms in treating cancers
❖
How do we deal with issues of cost and value
❖
How do we deal with patient selection
❖
What are the critical success factors for I/O agents
❖
How do we differentiate between different molecules
Welcome